Status:
COMPLETED
Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases
Lead Sponsor:
AbbVie
Conditions:
Ankylosing Spondylitis (AS)
Psoriasis
Eligibility:
All Genders
18-99 years
Brief Summary
The objective of this study is to evaluate the effect of adalimumab on health outcomes in participants with rheumatoid arthritis, ankylosing spondylitis and plaque psoriasis.
Eligibility Criteria
Inclusion
- Participants with a diagnosis of rheumatoid arthritis, ankylosing spondylitis or plaque psoriasis
- Decision to initiate Humira® treatment in accordance with routine medical practice and in compliance with eligibility for adalimumab based on the local label
- Prior to any study-specific procedures, participant has voluntarily signed the authorization (or informed consent where applicable) to disclose and use anonymized personal health information after participate in this research.
Exclusion
- Inadequate response to previous standard treatment with anti-tumor necrosis factor (TNF) biological agent according to the physician's clinical judgment.
- Participant has been treated with adalimumab within 70 days (five half-lives) prior to the Baseline Visit.
- Participants discontinued due to adverse drug reaction of previous adalimumab treatment.
- Participants who fulfill any of the contraindications as per adalimumab label in China.
- Participants, who in the clinician's view, may not be able to comply with the study requirements.
Key Trial Info
Start Date :
May 18 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 8 2021
Estimated Enrollment :
224 Patients enrolled
Trial Details
Trial ID
NCT03339089
Start Date
May 18 2018
End Date
July 8 2021
Last Update
July 8 2022
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Shenzhen Futian Hospital for rheumatic Diseases /ID# 209340
Shenzhen, Guangdong, China, 518040
2
AbbVie China /ID# 164373
Shanghai, Shanghai Municipality, China, 200041
3
The First affiliated hospital of chengdu medical university /ID# 210745
Chengdu, Sichuan, China, 610500
4
Zhejiang Province People's Hospital /ID# 209342
Hangzhou, Zhejiang, China, 310014